

ONO-4059 Study in Patients With Steroid-resistant Pemphigus

NCT06696716

Status	RECRUITING
Phase	Phase 3
Sponsor	Ono Pharmaceutical Co. Ltd
Enrollment	34 participants

Key Eligibility Criteria

Inclusion (2)

- Patients with a diagnosis of pemphigus
- Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg/day of prednisolone (PSL) equivalent

Exclusion (3)

- Patients with an active infection
- Patients with malignancy
- Patients with past history of serious allergy or anaphylaxis

Locations (25 total)

Ichinomiya Municipal Hospital, Aichi, Japan
Nagoya City University Hospital, Aichi, Japan
Ehime University Hospital, Ehime, Japan
... and 22 more locations